Novo Nordisk A/S (NYSE:NVO) Shares Purchased by WJ Wealth Management LLC

WJ Wealth Management LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 66.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,918 shares of the company’s stock after buying an additional 4,364 shares during the quarter. WJ Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,402,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Pacific Center for Financial Services increased its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. First PREMIER Bank acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $25,000. CNB Bank acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $26,000. Tyler Stone Wealth Management grew its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after buying an additional 146 shares during the last quarter. Finally, West Paces Advisors Inc. increased its position in Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock worth $27,000 after buying an additional 150 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 1.2 %

NYSE:NVO traded down $1.75 during trading hours on Friday, hitting $142.74. The stock had a trading volume of 2,757,544 shares, compared to its average volume of 3,502,773. The company has a market cap of $640.55 billion, a PE ratio of 49.22, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41. The business has a 50 day simple moving average of $135.00 and a two-hundred day simple moving average of $123.71. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $148.15. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.06. The firm had revenue of $9.52 billion for the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. Analysts predict that Novo Nordisk A/S will post 3.41 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. The Goldman Sachs Group assumed coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, June 17th. BMO Capital Markets reissued an “outperform” rating and set a $163.00 price target on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Finally, Argus lifted their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.67.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.